Dr. Harris is a gastroenterologist-hepatologist with broad expertise in industry and clinical trials in gastroenterology and liver diseases. He is currently Chief Medical Officer Altimmune, where he leads drug development programs in NASH, obesity, and hepatitis B. Previously, he was co-founder and Chief Medical Officer of Lyric Pharmaceuticals, Chief Medical Officer of Avaxia Biologics, and Chief Medical Officer of Ocera Therapeutics. Dr. Harris was Chief Medical Officer and vice president of Clinical Affairs at Napo Pharmaceuticals where he authored the pivotal clinical study that led to the approval of crofelemer (Mytesi®), the first Phase 2/3 adaptive trial design resulting in a drug approval. Scott sits on the faculty of Georgetown University School of Medicine where he directs a course on drug development under a CTSA grant from the NIH. He has been a consultant on third-world drug development for the Bill and Melinda Gates Foundation and a speaker at national and international forums on drug development. Scott has an M.D. from Harvard Medical School and an MS in Administrative Medicine and Population Health from the University of Wisconsin Medical School. His post-graduate training includes residencies at John Hopkins Hospital and the University of Pennsylvania, and a Gastroenterology and Hepatology Fellowship at the Yale University School of Medicine. Prior to entering industry, he served as Professor of Medicine and Chief of Gastroenterology at the University of Wisconsin in Milwaukee. His drug development experience includes hepatic encephalopathy, inflammatory bowel disease, and a multitude of gastroenterology and liver disorders.
